Pfizer’s Ibrance clears first hurdle to early access in U.K.

Carly Helfand

Pfizer's new cancer standout, , has taken its step toward joining the 's to Medicines program, winning the "promising innovative medicine" tag from the country's Medicines and Healthcare Regulatory Agency.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS